|
|
|
|
A 41-gene signature derived from breast cancer stem cells as a predictor of survival
|
|
|
|
|
|
|
|
نویسنده
|
yin z.-q. ,liu j.-j. ,xu y.-c. ,yu j. ,ding g.-h. ,yang f. ,tang l. ,liu b.-h. ,ma y. ,xia y.-w. ,lin x.-l. ,wang h.-x.
|
|
منبع
|
journal of experimental and clinical cancer research - 2014 - دوره : 33 - شماره : 1
|
|
چکیده
|
Purpose. the aim of this study was to evaluate the ability of a 41-gene signature derived from breast cancer stem cells (bcscs) to estimate the risk of metastasis and survival in breast cancer patients. methods. the centroid expression of the 41-gene signature derived from bcscs was applied as the threshold to classify patients into two separate groups - patients with high expression (high-el) of the prognostic signature and patients with low expression (low-el). the predictive ability of the 41-gene signature was evaluated by cox regression model and was compared against other popular tests,such as oncotype and mammaprint. results: our results showed that the 41-gene prognostic signature was significantly associated with age (p =.0351) and er status (p =.0095). the analysis indicated that patients in the high-el group had a worse prognosis than those in the low-el group in terms of both overall survival (os: hr,2.05,p =.009) and distant metastasis-free survival (dmfs: hr,2.24,p =.002). additionally,the 41-gene signature was an independent risk factor and separates patients based on estrogen receptor status. while comparable to oncotype,the analysis demonstrated that the 41-gene signature had a better prognostic value in predicting dmfs and os than aol,npi,st. gallen,veridex,and mammaprint. conclusions: this study confirms the utility of the 41-gene signature and adds to the growing evidence that gene expression signatures of bcscs have clinical potential to predict patient outcome and aid in treatment choice. © 2014yin et al.; licensee biomed central ltd.
|
|
کلیدواژه
|
Breast cancer; Prognostic signature; Stem cell
|
|
آدرس
|
shanghai renji hospital,shanghai jiaotong university school of medicine,shanghai,200127, China, shanghai renji hospital,shanghai jiaotong university school of medicine,shanghai,200127, China, shanghai renji hospital,shanghai jiaotong university school of medicine,shanghai,200127, China, shanghai center for bioinformation technology,shanghai,201203, China, shanghai center for bioinformation technology,shanghai,201203, China, shanghai renji hospital,shanghai jiaotong university school of medicine,shanghai,200127, China, shanghai renji hospital,shanghai jiaotong university school of medicine,shanghai,200127, China, shanghai center for bioinformation technology,shanghai,201203, China, shanghai renji hospital,shanghai jiaotong university school of medicine,shanghai,200127, China, shanghai renji hospital,shanghai jiaotong university school of medicine,shanghai,200127, China, shanghai renji hospital,shanghai jiaotong university school of medicine,shanghai,200127, China, shanghai renji hospital,shanghai jiaotong university school of medicine,shanghai,200127,china,department of oncology,shanghai jiaotong university,renji hospital,shanghai,200127, China
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Authors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|